Key clinical point: This meta-analysis suggests that the use of androgen receptor inhibitors (ARIs; enzalutamide, apalutamide, or darolutamide) is associated with an increased risk of fall and fracture in patients with prostate cancer.

Major finding: In the pooled analysis, use of ARI was associated with a higher risk of all-grade falls (relative risk [RR], 1.80; P less than .001), grade 3 or greater fall (RR, 1.60; P less than .001), all-grade fractures (RR, 1.59; P less than .001), and likely grade 3 or greater fracture (RR, 1.71; P = .01).

Study details: A meta-analysis of 11 randomized clinical trials including 11,382 men with a median age of 72 years (6,536 men were in the ARI group and 4,846 men were in the control group).

Disclosures: No study sponsor was identified. Dr. J. M. Kolesar reported receiving ownership interest from Helix Diagnostics outside the submitted work. No other disclosures were reported.